Stereotaxis (NYSEAMERICAN:STXS) Stock Price Down 2.2% – Here’s What Happened

Stereotaxis, Inc. (NYSEAMERICAN:STXS)’s stock price fell 2.2% during trading on Thursday . The stock traded as low as $2.18 and last traded at $2.19. 271,151 shares were traded during mid-day trading, a decline of 12% from the average session volume of 306,758 shares. The stock had previously closed at $2.24.

Stereotaxis Trading Up 6.8 %

The stock has a market cap of $198.27 million, a price-to-earnings ratio of -8.36 and a beta of 1.57.

Stereotaxis (NYSEAMERICAN:STXS) last posted its earnings results on Monday, November 11th. The company reported ($0.08) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.03). The business had revenue of $9.20 million for the quarter, compared to the consensus estimate of $6.80 million. Stereotaxis had a negative return on equity of 162.54% and a negative net margin of 85.79%. As a group, equities research analysts forecast that Stereotaxis, Inc. will post -0.26 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. SG Americas Securities LLC bought a new stake in shares of Stereotaxis in the 3rd quarter valued at $39,000. Forum Financial Management LP acquired a new position in Stereotaxis in the second quarter valued at $48,000. Jane Street Group LLC boosted its position in Stereotaxis by 26.9% during the third quarter. Jane Street Group LLC now owns 29,773 shares of the company’s stock valued at $61,000 after acquiring an additional 6,313 shares during the last quarter. Rhumbline Advisers grew its holdings in Stereotaxis by 645.6% during the 2nd quarter. Rhumbline Advisers now owns 48,251 shares of the company’s stock worth $88,000 after acquiring an additional 41,780 shares during the period. Finally, Barclays PLC raised its position in shares of Stereotaxis by 449.9% in the 3rd quarter. Barclays PLC now owns 101,953 shares of the company’s stock worth $208,000 after acquiring an additional 83,412 shares in the last quarter. Institutional investors own 45.35% of the company’s stock.

Stereotaxis Company Profile

Stereotaxis, Inc designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally. Its robotic magnetic navigation (RMN) systems include the Genesis RMN and Niobe systems, which enable physicians to complete complex interventional procedures by providing image-guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites.